Balmain Beauty Introduces Destin de Balmain: A New Prestige Fragrance
20.2.2026 08:30:00 CET | Business Wire | Press Release
Balmain Beauty unveils Destin de Balmain, its debut prestige fragrance. The new feminine fragrance is a bold, floral fruity eau de parfum that captures the unstoppable energy of the Balmain woman: independent, youthful, and unapologetic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219851364/en/
Destin de Balmain (Photo Credit: Balmain Beauty)
THE STORY: LIVE YOUR DESTINY
Destin de Balmain is destiny you hold in your hands, a journey of optimism and infinite possibilities. The refillable fragrance unites those who express themselves without rules or expectations. Inspired by the Parisian House’s savoir-faire and modern pulse, the daring fragrance celebrates choosing your path and living your destiny.
“Destin de Balmain features a joyful, optimistic spark of ripe strawberry,” said Quentin Bisch, Perfumer. “The fruit’s juicy vivacity brings bright, elevated sweetness to the composition. Notes of peony further convey the feeling of rosy fullness, and notes of creamy sandalwood anchor the fragrance in strength and luminosity. It has an irresistible electric energy.”
THE FRAGRANCE: A BOLD, FLORAL FRUITY SCENT
Destin de Balmain captures the thrill of new beginnings with radiant and ripe strawberry, notes of rosy peony and creamy sandalwood.
The vibrant burst of neon-saturated, naturally-sourced strawberry playfully contrasts with the spicy pepper notes of baies rose. Notes of peony reveal unexpected creamy lychee facets.
The fragrance’s floralcy deepens with a lily accord. Its delicate green note and the intense spice of Akigalawood™ come together, intermingling with a sandalwood accord and smooth patchouli for a radiant woody effect. The brilliant, musky second-skin scent of Ambrexolide™ grounds the composition in an unforgettable, sensual warmth.
THE BOTTLE: INSPIRED BY THE ICONIC BALMAIN LABYRINTH
The fragrance is contained in a precious, refillable glass cube, capped with signature golden striations. The PB monogram runs across every face, carving the House’s iconic Labyrinth motif into three-dimensional pathways. Clear and gold, and full of spark, it encapsulates the undeniable spirit of the scent.
Destin de Balmain is available worldwide in Balmain boutiques, online, and at select fashion and beauty destinations. The fragrance comes in a 10 ml travel spray and 30 ml, 50 ml, 100 ml, and 150 ml bottles.
Follow the brand on social media at @balmainbeauty (Instagram), @balmainbeauty (TikTok), and visit www.balmainbeauty.com to learn more.
About Balmain Beauty
Balmain Beauty extends the storied legacy of the Parisian fashion House founded in 1945 by Pierre Balmain into a new era of luxury beauty. Balmain embodies contemporary elegance, culture, and sensuality, inspiring fragrances that celebrate bold self-expression. Balmain Beauty introduced its inaugural all-gender luxury fragrance collection, Les Éternels, in 2024, and its first prestige fragrance, Destin de Balmain, in 2026. Balmain Beauty was established in 2022 under a license agreement between Balmain and The Estée Lauder Companies and is proudly certified with a Butterfly Mark for its commitment to sustainability.
About Balmain
BALMAIN is a Parisian luxury fashion House founded in 1945 by Pierre Balmain, the visionary behind the iconic “New French Style.” Under the creative direction of French-born designer Antonin Tron, the Maison embodies contemporary elegance while honoring more than 80 years of heritage. Alongside women’s and men’s ready-to-wear and accessory collections, the Maison engages its global audience with Balmain Beauty, a prestige beauty line licensed to The Estée Lauder Companies and inspired by the brand’s iconic 1940s and 1950s fragrances.
ELC-B
View source version on businesswire.com: https://www.businesswire.com/news/home/20260219851364/en/
Contacts
Media Contact
Sarah Moreau
smoreau@balmainbeauty.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom